Overview

Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of single doses of SBI-087 in subjects with rheumatoid arthritis.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Collaborator:
Emergent Product Development Seattle LLC